"Diclofenac" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
| Descriptor ID |
D004008
|
| MeSH Number(s) |
D02.241.223.601.210
|
| Concept/Terms |
Diclofenac- Diclofenac
- Diclophenac
- Dicrofenac
- Dichlofenal
|
Below are MeSH descriptors whose meaning is more general than "Diclofenac".
Below are MeSH descriptors whose meaning is more specific than "Diclofenac".
This graph shows the total number of publications written about "Diclofenac" by people in this website by year, and whether "Diclofenac" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diclofenac" by people in Profiles.
-
Kabir MF, Jackson JL, Fuller AD, Gathuka L, Karami AL, Conde DG, Klochkova A, Mu A, Cai KQ, Klein-Szanto AJ, Muir AB, Whelan KA. Diclofenac exhibits cytotoxic activity associated with metabolic alterations and p53 induction in ESCC cell lines and decreases ESCC tumor burden in vivo. Carcinogenesis. 2023 05 26; 44(2):182-195.
-
Jones Lipinski RA, Thillier Y, Morisseau C, Sebastiano CS, Smith BC, Hall CD, Katritzky AR. Molecular docking-guided synthesis of NSAID-glucosamine bioconjugates and their evaluation as COX-1/COX-2 inhibitors with potentially reduced gastric toxicity. Chem Biol Drug Des. 2021 07; 98(1):102-113.
-
Gibofsky A, Silberstein S, Argoff C, Daniels S, Jensen S, Young CL. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med. 2013 Sep; 125(5):130-8.
-
Silberstein SD. Meeting acute migraine treatment needs through novel treatment formulations. Neurotherapeutics. 2010 Apr; 7(2):153-8.
-
Davenport K, Timoney AG, Keeley FX. Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: a pilot study. Urol Res. 2007 Aug; 35(4):207-13.
-
Davenport K, Timoney AG, Keeley FX. A comparative in vitro study to determine the beneficial effect of calcium-channel and alpha(1)-adrenoceptor antagonism on human ureteric activity. BJU Int. 2006 Sep; 98(3):651-5.
-
Packman E, Packman B, Thurston H, Tseng L. Lumiracoxib is effective in the treatment of episodic tension-type headache. Headache. 2005 Oct; 45(9):1163-70.
-
Gabison EE, Chastang P, Menashi S, Mourah S, Doan S, Oster M, Mauviel A, Hoang-Xuan T. Late corneal perforation after photorefractive keratectomy associated with topical diclofenac: involvement of matrix metalloproteinases. Ophthalmology. 2003 Aug; 110(8):1626-31.
-
Lin JC, Rapuano CJ, Laibson PR, Eagle RC, Cohen EJ. Corneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgery. Arch Ophthalmol. 2000 Aug; 118(8):1129-32.
-
Szucs PA, Nashed AH, Allegra JR, Eskin B. Safety and efficacy of diclofenac ophthalmic solution in the treatment of corneal abrasions. Ann Emerg Med. 2000 Feb; 35(2):131-7.